Hostname: page-component-78c5997874-lj6df Total loading time: 0 Render date: 2024-11-10T10:13:41.606Z Has data issue: false hasContentIssue false
  • English
  • Français

Citalopram in mentally retarded patients with depression: a long-term clinical investigation

Published online by Cambridge University Press:  16 April 2020

W.M.A. Verhoeven ,
M.J. Veendrik-Meekes ,
G.A.J. Jacobs ,
Y.W.M.M. van den Berg  and
S. Tuinier
W.M.A. Verhoeven*
Affiliation:
Vincent van Gogh Institute for Psychiatry, Stationsweg 46, 5803 AC Venray, The Netherlands
M.J. Veendrik-Meekes
Affiliation:
Institute for Epilepsy Kempenhaeghe, Heeze, The Netherlands
G.A.J. Jacobs
Affiliation:
Institute for Mental Retardation “Saamvliet,” Gennep, The Netherlands
Y.W.M.M. van den Berg
Affiliation:
Vincent van Gogh Institute for Psychiatry, Stationsweg 46, 5803 AC Venray, The Netherlands
S. Tuinier
Affiliation:
Vincent van Gogh Institute for Psychiatry, Stationsweg 46, 5803 AC Venray, The Netherlands
*
*Correspondence and reprints.
Get access

Abstract

The effect of citalopram was investigated in 20 mentally retarded patients suffering from a depressive disorder characterized by alterations in the domains of affectivity, motivation, motor activity and vital signs. The study followed a baseline-controlled open design. Citalopram was started in a daily dosage of 20 mg that was kept unchanged for 6 weeks. Thereafter dosage was adjusted to maximally 60 mg per day. Treatment effects were assessed according to the Clinical Global Improvement Scale (CGIS) after at least 6 months.

In 12 of the 20 patients a moderate to marked improvement in all domains was observed upon treatment with 20–40 mg citalopram daily. Treatment for one year in the effective dose prevented recurrence of depressive symptomatology. Concomitant use of sedative anticonvulsants reduced responsiveness to treatment. No interactions were observed.

It is concluded that citalopram is a well-tolerated, safe and effective antidepressant in mentally retarded subjects with depressive disorders.

Keywords

citalopramdepressioninteractionsmental retardationself-injurious behaviourstereotypies
Type
Original article
Information
European Psychiatry , Volume 16 , Issue 2 , March 2001 , pp. 104 - 108
Copyright
Copyright © Éditions scientifiques et médicales Elsevier SAS 2001

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Charlot, L.R, Doucette, A.C, Mezzacappa, EAffective symptoms of institutionalized adults with mental retardation Am J Mental Retard 1993; 8: 408–416.Google Scholar
Flint, JBehavioural phenotypes: conceptual and methodological issues Am J Med Genet 1998; 81: 235–240.Google Scholar
Franchini, L, Zanardi, R, Gasperini, M, Smeraldi, ETwo-year maintenance treatment with citalopram, 20 mg, in unipolar subjects with high recurrence rate J Clin Psychiatry 1999; 60: 861–865.Google Scholar
Gottfries, C.GRecognition and management of depression in the elderly Int Clin Psychopharmacol 1997; 12: S31–S36.CrossRefGoogle Scholar
Gottfries, C.GScandinavian experience with citalopram in the elderly Int Clin Psychopharmacol 1996; 11: S41–S44.CrossRefGoogle Scholar
Guy, WEarly clinical drug evaluation (ECDEU) assessment manual Rockville (MD): National Institute on Mental Health; 1976.Google Scholar
Joffe, P, Larsen, F.S, Perdersen, V, Ring-Larsen, H, Aaes-Jorgensen, T, Sidhu, JSingle dose pharmacokinetics of citalopram in patients with moderate renal insufficiency or hepatic cirrhosis compared with healthy subjects Eur J Clin Pharmacol 1998; 54: 237–242.Google ScholarPubMed
Ketter, T.A, Post, R.M, Theodore, W.HPositive and negative psychiatric effects of antiepileptic drugs in patients with seizure disorders Neurology 1999; 53: S53–S67.Google Scholar
Lewis, M.H, Gluck, J.P, Bodfish, J.W, Brauchamp, A.J, Mailman, R.BNeurobiological basis of stereotyped movement disorderSprague, R.L, Newell, K.MStereotyped movements; brain and behaviour relationships Washington DC: American Psychological Association; 1996. p. 37–68.CrossRefGoogle Scholar
Marston, G.M, Perry, D.W, Roy, AManifestations of depression in people with intellectual disability J Intellect Disabil Res 1997; 41: 476–480.Google Scholar
Meins, WA new depression scale designed for use with adults with mental retardation J Intellect Disabil Res 1996; 40: 222–226.Google Scholar
Meins, WSymptoms of major depression in mentally retarded adults J Intellect Disabil Res 1995; 39: 41–45.Google Scholar
Meins, WWie werden geistig behinderte Erwachsene mit depressiven Störungen psychopharmacologisch behandelt? Nervenartzt 1996; 67: 216–218.Google Scholar
Menolascino, F.J, Gilson, S.F, Levitas, A.SIssues in the treatment of mentally retarded patients in the community mental health system Community Ment Health J 1986; 22: 314–327.Google Scholar
Myers, B.A, Pueschel, S.MMajor depression in a small group of adults with Down syndrome Res Dev Disabil 1995; 16: 289–299.Google Scholar
Myers, B.APsychopathology in hospitalized developmentally disabled individuals Compr Psychiatry 1986; 27: 115–126.Google Scholar
Noble, S, Benfield, PCitalopram. A review of its pharmacology, clinical efficacy and tolerability in the treatment of depression CNS Drugs 1997; 8: 410–431.Google Scholar
Praag, H.MBarking up the wrong tree. Towards a more effective system of psychiatric diagnosing Neuropsychopharmacology 1993; 9: S52–S53.Google Scholar
Praag, H.MInflationary tendencies in judging the field of depression research Neuropsychobiology 1998; 37: 130–141.Google Scholar
Rasmussen, S.L, Overo, K.F, Tanghoj, PCardiac safety of citalopram: prospective trials and retrospective analyses J Clin Psychopharmacol 1999; 19: 407–415.Google Scholar
Sproule, B.A, Naranjo, C.A, Brenmer, K.E, Hassan, P.CSelective serotonin reuptake inhibitors and CNS drug interactions. A critical review of the evidence Clin Pharmacokinet 1997; 33: 454–471.Google Scholar
Syvalahti, E.K, Taiminen, T, Saarijarvi, S, Lehto, H, Niemi, H, Ahola, Vet al.Citalopram causes no significant alterations in plasma neuroleptic levels in schizophrenic patients J Int Med Res 1997; 25: 24–32.Google Scholar
Turk, J, Hill, PBehavioural phenotypes in dysmorphic syndromes Clin Dysmorphology 1995; 4: 105–115.Google Scholar
Verhoeven, W.M.A, Tuinier, SThe serotonin syndrome: four case reports and a concise review of the literature Eur J Psychiatry 1998; 12: 12–18.Google Scholar
Verhoeven, W.M.A, Tuinier, SThe psychopharmacology of challenging behaviours in developmental disabilitiesBouras, NPsychiatric and behavioural disorders in mental retardation Cambridge: Cambridge University Press; 1999. p. 295–316.Google ScholarPubMed
Verhoeven, W.M.A, Tuinier, S, Van den Berg, Y.W.M.M, Coppus, A.M.W, Fekkes, D, Pepplinkhuizen, Let al.Stress and self-injurious behaviour: hormonal and serotonergic parameters in mentally retarded subjects Pharmacopsychiatry 1999; 32: 13–20.Google Scholar
Wiegartz, P, Seidenberg, M, Woodard, A, Gidal, B, Hermann, BComorbid psychiatric disorder in chronic epilepsy: recognition and etiology of depression Neurology 1999; 53: S3–S8.Google Scholar
Submit a response

Comments

No Comments have been published for this article.